| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Departments of Pathology [V. E. W., T. R. S.] and Environmental Sciences and Engineering [T. R. S., T. R. C.], University of North Carolina, Chapel Hill, North Carolina, 27599; The Procter and Gamble Company, Miami Valley Laboratories, Cincinnati, Ohio 45253-8707 [N. J. G., J. L. A.]; Biology Department, Center for Environmental Health, University of Victoria, Victoria, British Columbia V8W 2Y2, Canada [J. G. d., B. W. G.]; and Wadsworth Center for Laboratories and Research, New York State Department of Health, Albany, New York 12201-0509 [V. E. W.]
The development of mouse models with the endogenous hypoxanthineguanine phosphoribosyl transferase (hprt) gene and lacI transgene as mutational targets provides an excellent opportunity to compare the mutant frequency (Mf) and types of mutations induced in vivo in different sequence contexts. To this end, a study was conducted to determine the Mfs and spectrum of mutations induced at these loci in splenic T cells from male B6C3F1 Big Blue mice (6 weeks old) exposed to N-ethyl-N-nitrosourea (ENU). Six weeks after i.p. injection of 40 mg ENU/kg, T cells were isolated from control (n = 7) and treated (n = 8) mice for the culture of hprt mutants and for the extraction of DNA and recovery of lacI mutants. Mutations in hprt exon 3 and in lacI were quantified and analyzed using published procedures (S. W. Kohler et al., Proc. Natl. Acad. Sci. USA, 88: 7958–7962, 1991; T. R. Skopek et al., Proc. Natl. Acad. Sci. USA, 89: 7866–7870, 1992). In treated mice, the Mfs (average ± SE) in hprt (6.0 ± 0.2 x 10-5) and lacI (11.4 ± 1.8 x 10-5) were approximately 16.2-fold (P = 0.096) and 3.4-fold (P = 0.009), respectively, above controls. However, the average induced Mfs (i.e., induced Mf = treatment Mf — background Mf) in hprt and lacI were similar, with the respective increases in Mf being 5.6 ± 0.2 x 10-5 and 8.0 ± 2.3 x 10-5 over background. Eleven of the 107 hprt mutants from treated Big Blue mice had mutations in exon 3, with 73% being substitutions at A·T bp. These data are similar to those observed in ENU-exposed nontransgenic B6C3F1 mice, in which 62 of 69 exon 3 mutations were substitutions at A·T bp (T. R. Skopek et al., Proc. Natl. Acad. Sci. USA, 89: 7866–7870, 1992). For comparison, the sequences of the lacI genes in two to five mutants from each mouse were determined, and a total of 75 mutations (70 different mutations) was detected. In exposed mice, 55% (24 of 44) of the mutations in lacI were substitutions at A·T bp. In controls, substitutions at AT bp comprised only 20% of the recovered mutations in either hprt exon 3 (1 of 5) or lacI (5 of 26). These data indicate that the lacI mutation assay is less sensitive than the hprt assay for detecting increases in Mf induced by ENU exposure of mice as indicated by the lower relative increase in Mf in the lacI gene, but, given a 6-week expression time, the types of mutations induced by ENU in the transgene reflect those observed in the native transcribed gene.
1 Funded in part by grants from the Procter and Gamble Co. and National Institute of Environmental Health Sciences Grant P42-ES0594801.
2 To whom requests for reprints should be addressed, at the Wadsworth Center for Laboratories and Research, New York State Department of Health, Albany, NY 122010509.
Received 4/22/96. Accepted 8/14/96.
This article has been cited by other articles:
![]() |
C. R. Valentine, H. F. Rainey, J. M. Farrell, J. G. Shaddock, V. N. Dobrovolsky, and R. R. Delongchamp Frequency and spectrum of ENU-induced mutation in the {Phi}X174 transgene in mouse splenic lymphocytes and their significance to spontaneous transgenic rodent mutation frequencies Mutagenesis, September 1, 2008; 23(5): 383 - 397. [Abstract] [Full Text] [PDF] |
||||
![]() |
W. Slikker III, N. Mei, and T. Chen N-Ethyl-N-nitrosourea (ENU) Increased Brain Mutations in Prenatal and Neonatal Mice but Not in the Adults Toxicol. Sci., September 1, 2004; 81(1): 112 - 120. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. S. Turker Autosomal mutation in somatic cells of the mouse Mutagenesis, January 1, 2003; 18(1): 1 - 6. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. R. Stuart and B. W. Glickman Through a Glass, Darkly: Reflections of Mutation From lacI Transgenic Mice Genetics, July 1, 2000; 155(3): 1359 - 1367. [Abstract] [Full Text] |
||||
![]() |
G. R. Stuart, Y. Oda, J. G. de Boer, and B. W. Glickman Mutation Frequency and Specificity With Age in Liver, Bladder and Brain of lacI Transgenic Mice Genetics, March 1, 2000; 154(3): 1291 - 1300. [Abstract] [Full Text] |
||||
![]() |
E. Okochi, N. Watanabe, Y. Shimada, S. Takahashi, K. Wakazono, T. Shirai, T. Sugimura, M. Nagao, and T. Ushijima Preferential induction of guanine deletion at 5'-GGGA-3' in rat mammary glands by 2-amino- 1-methyl-6-phenylimidazo[4,5-b]pyridine Carcinogenesis, October 1, 1999; 20(10): 1933 - 1938. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Davies, T. W. Gant, L. L. Smith, and J. A. Styles Tamoxifen induces G:C->T:A mutations in the cII gene in the liver of lambda/lacI transgenic rats but not at 5'-CpG-3' dinucleotide sequences as found in the lacI transgene Carcinogenesis, July 1, 1999; 20(7): 1351 - 1356. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. W. P. Wijnhoven, P. P. H. Van Sloun, H. J. M. Kool, G. Weeda, R. Slater, P. H. M. Lohman, A. A. van Zeeland, and H. Vrieling Carcinogen-induced loss of heterozygosity at the Aprt locus in somatic cells of the mouse PNAS, November 10, 1998; 95(23): 13759 - 13764. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. P. O'Neill DNA damage, DNA repair, cell proliferation, and DNA replication: How do gene mutations result? PNAS, October 10, 2000; 97(21): 11137 - 11139. [Full Text] [PDF] |
||||
![]() |
R. N. Winn, M. B. Norris, K. J. Brayer, C. Torres, and S. L. Muller Detection of mutations in transgenic fish carrying a bacteriophage lambda cII transgene target PNAS, November 7, 2000; 97(23): 12655 - 12660. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |